Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
|Videos|February 15, 2021
Addressing the gaps in AMD treatment
Author(s)OT Staff Reports
Aleksandra Rachitskaya, MD, speaks on the current gaps in AMD treatment as well as ongoing retinal advancements to help address unmeet needs of patients.
Advertisement
Advertisement
Related to this article
Sura-vec is a 1-time investigational gene therapy designed to deliver sustained treatment in wet AMD, diabetic retinopathy and other chronic retinal conditions.
The trial over-enrolled and finished approximately 4 months ahead of initial projections, with 52-week topline data now expected in the second half of 2027.
Ultra-widefield imaging reveals early retinal risk in pediatric patients.
Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.
The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.
Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.
The resubmission is considered a Class 1 submission and has a current PDUFA target action date of July 29, 2026.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Comments from the FDA Advisory Committee meeting on SYD-101
2
OCT-980 receives FDA orphan drug designation for retinitis pigmentosa
3
FAQ: Diabetic eye disease awareness month 2026
4
First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP
5